Report Tools

Biotechnology in Canada

Published: August 2013 · Publisher: MarketLine
Biotechnology in Canada industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017).
Report Type Industry Profiles
Language English
Format Electronic (PDF)
Pages35
Frequency Updated Annually
Availability Will be emailed within 1 business day
Reference No. 0109-6777
Price € 259,00
Options
  • Description
  • Companies Mentioned
  • Table of Contents
  • Ask a Question
Introduction

Biotechnology in Canada industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Canada biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.

*The Canadian biotechnology market had total revenues of $3.6bn in 2012, representing a compound annual rate of change (CARC) of -5.6% between 2008 and 2012.

*Canada has the leading R&D and supportive innovation climate and the country boasts the second highest concentration of biotechnology firms globally. The research centers are securing large investments from global multinational biopharmaceutical companies, and are attracting partnerships in emerging technologies, such as clean technology, stem cells, and nanotech.

*The performance of the market is forecast to accelerate, with an anticipated CAGR of 9.2% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $5.5bn by the end of 2017.

Features

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Canada

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Canada

Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Canada biotechnology market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Canada economy

Key Questions Answered

What was the size of the Canada biotechnology market by value in 2012?

What will be the size of the Canada biotechnology market in 2017?

What factors are affecting the strength of competition in the Canada biotechnology market?

How has the market performed over the last five years?

What are the main segments that make up Canada's biotechnology market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
#N/A
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 14
New entrants 15
Threat of substitutes 16
Degree of rivalry 17
Leading Companies 18
Amgen, Inc. 18
Baxter International Inc. 21
Covance Inc. 24
Novartis AG 27
Macroeconomic Indicators 31
Country Data 31
Appendix 33
Methodology 33
Industry associations 34
Related research 34

LIST OF TABLES
Table 1: Canada biotechnology market value: $ billion, 2008–12 8
Table 2: Canada biotechnology market category segmentation: $ billion, 2012 9
Table 3: Canada biotechnology market geography segmentation: $ billion, 2012 10
Table 4: Canada biotechnology market value forecast: $ billion, 2012–17 11
Table 5: Amgen, Inc.: key facts 18
Table 6: Amgen, Inc.: key financials ($) 19
Table 7: Amgen, Inc.: key financial ratios 19
Table 8: Baxter International Inc.: key facts 21
Table 9: Baxter International Inc.: key financials ($) 22
Table 10: Baxter International Inc.: key financial ratios 22
Table 11: Covance Inc.: key facts 24
Table 12: Covance Inc.: key financials ($) 25
Table 13: Covance Inc.: key financial ratios 25
Table 14: Novartis AG: key facts 27
Table 15: Novartis AG: key financials ($) 28
Table 16: Novartis AG: key financial ratios 29
Table 17: Canada size of population (million), 2008–12 31
Table 18: Canada gdp (constant 2000 prices, $ billion), 2008–12 31
Table 19: Canada gdp (current prices, $ billion), 2008–12 31
Table 20: Canada inflation, 2008–12 32
Table 21: Canada consumer price index (absolute), 2008–12 32
Table 22: Canada exchange rate, 2008–12 32

LIST OF FIGURES
Figure 1: Canada biotechnology market value: $ billion, 2008–12 8
Figure 2: Canada biotechnology market category segmentation: % share, by value, 2012 9
Figure 3: Canada biotechnology market geography segmentation: % share, by value, 2012 10
Figure 4: Canada biotechnology market value forecast: $ billion, 2012–17 11
Figure 5: Forces driving competition in the biotechnology market in Canada, 2012 12
Figure 6: Drivers of buyer power in the biotechnology market in Canada, 2012 13
Figure 7: Drivers of supplier power in the biotechnology market in Canada, 2012 14
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in Canada, 2012 15
Figure 9: Factors influencing the threat of substitutes in the biotechnology market in Canada, 2012 16
Figure 10: Drivers of degree of rivalry in the biotechnology market in Canada, 2012 17
Figure 11: Amgen, Inc.: revenues & profitability 20
Figure 12: Amgen, Inc.: assets & liabilities 20
Figure 13: Baxter International Inc.: revenues & profitability 22
Figure 14: Baxter International Inc.: assets & liabilities 23
Figure 15: Covance Inc.: revenues & profitability 25
Figure 16: Covance Inc.: assets & liabilities 26
Figure 17: Novartis AG: revenues & profitability 29
Figure 18: Novartis AG: assets & liabilities 30
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.